Welcome to our dedicated page for Revolution Medicines SEC filings (Ticker: RVMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Revolution Medicines, Inc. filings document a late-stage clinical oncology company focused on RAS-addicted cancers and RAS(ON) inhibitors. Its Form 8-K reports include financial results, clinical-program updates for daraxonrasib and other pipeline candidates, regulatory-related disclosures and material events tied to corporate progress.
The company’s SEC record also covers proxy governance, annual meeting matters, executive compensation, registered securities and capital-structure changes. Disclosures identify Nasdaq-listed common stock and warrants, and material-agreement filings describe convertible senior notes due 2033, related indenture terms and other financing arrangements used to support research and development, administrative expenses and potential commercialization activities.
Form 144 notice for Revolution Medicines, Inc. (RVMD) reporting a proposed sale of 10,000 common shares acquired and to be sold on 09/02/2025 following an exercise of stock options. The broker listed is Morgan Stanley Smith Barney LLC and the aggregate market value of the shares at filing is $379,700.00. The filing states the issuer has 186,933,190 shares outstanding. The seller previously disposed of 2,170 common shares on 06/16/2025 for $86,431.10. The filer affirms no undisclosed material adverse information and includes standard Rule 10b5-1/attestation language.
Baker Bros. Advisors and related persons report beneficial ownership of 9,364,972 shares of Revolution Medicines, Inc. common stock, representing 5.0% of 186,901,268 shares outstanding as of June 30, 2025. The holdings are held through two funds: 667, L.P. (0.4%) and Baker Brothers Life Sciences, L.P. (4.6%). The filing states the Adviser has sole voting and dispositive power over the funds' securities under management agreements and that certain prefunded warrants exist but cannot currently be exercised because of a 4.99% ownership cap on exercise.
Janus Henderson Group plc reports a passive, non-controlling stake in Revolution Medicines common stock, with disclosed shared voting and dispositive power in the range of 10.45–10.59 million shares, representing about 5.6%–5.7% of the class. The filing identifies both a group-level beneficial figure of 10,590,727 shares (5.7%) and a related subsidiary position of 10,445,374 shares (5.6%), indicating Janus Henderson exercises shared voting and disposition rights over these holdings.
The statement certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing also includes a power-of-attorney authorizing compliance signatories to execute and amend related ownership reports on the company's behalf.
Revolution Medicines (RVMD) filed a Form 4 for director Alexis Borisy covering transactions on 26 June 2025.
- 3,142 Restricted Stock Units (RSUs) were acquired at no cost, lifting his direct common-stock position to 2,338,884 shares.
- A new stock-option grant for 11,574 shares was issued at an exercise price of $37.48, expiring on 26 Jun 2035; the award vests in full on the earlier of the first anniversary or the next annual meeting, assuming continued service.
No shares were sold, so Mr. Borisy’s net exposure to RVMD equity increased. Although the incremental RSU amount is small relative to his existing 2.3 million-share stake, the at-the-money option grant and additional RSUs reinforce alignment between the director and shareholders by incentivizing future price appreciation.